The U.S. Food and Drug Administration (FDA) is focused on preventing and mitigating medical device shortages, which pose significant risks to patient care, particularly for vulnerable populations like neonatal and pediatric patients. From premature infants in neonatal intensive care units to children with chronic illnesses requiring long-term medical interventions, the need for appropriately sized, high-quality devices is paramount.
The causes of these shortages are varied, including natural disasters, manufacturing limitations, quality issues, and lack of investment in pediatric-specific devices. To address this, the FDA’s Office of Supply Chain Resilience (OSCR) actively monitors supply chains and manages a medical device shortages list, requiring manufacturers to notify the agency in advance of production disruptions.
To enhance these efforts, the FDA has requested expanded authority to enforce earlier shortage reporting and additional funding for its supply chain program. Moving forward, collaboration among the FDA, health care providers, policymakers, and manufacturers will be critical to ensuring continuous access to essential medical devices for all patient populations.
Read the full CDRH Statement here.
